First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy Adults

Summary

This study will assess the safety, tolerability, and pharmacokinetic properties of GSK4425689A monoclonal antibody (mAb) in healthy adults, when administered by either intravenous (IV) or subcutaneous (SC) routes.

Timeline

Start

2026-06-12

Primary completion

2028-04-19

Completion

2028-04-19

Drugs

Indications